GO:0031781 type 3 melanocortin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031781 (type 3 melanocortin receptor binding) is a molecular function describing the binding of a ligand to the type 3 melanocortin receptor (MC3R), a class A G-protein-coupled receptor.
• MC3R is a central regulator of energy homeostasis, inflammation, and neuroendocrine function, and its binding activity is modulated by accessory proteins such as MRAP2.
• The melanocortin system, including MC3R, is genetically linked to obesity and metabolic disease; gain-of-function MC4R variants protect against obesity, highlighting the therapeutic relevance of melanocortin receptor signaling.
• MRAP2 directly interacts with MC3R to enhance its signaling, providing a key regulatory mechanism for receptor binding and downstream activation.
• Dysregulation of melanocortin receptor binding is implicated in inflammatory conditions, and MC3R has been proposed as a potential target for anti-inflammatory therapy.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential to dissect the causal role of MC3R and its binding partners in metabolic and inflammatory diseases.
Description
GO:0031781, type 3 melanocortin receptor binding, is a molecular function term that describes the selective interaction of a ligand with the type 3 melanocortin receptor (MC3R), a member of the melanocortin receptor family of G-protein-coupled receptors. This binding event is the first step in MC3R-mediated signal transduction, which regulates diverse physiological processes including energy balance, inflammation, and neuroendocrine signaling. Understanding this binding function is critical because MC3R and its ligands are emerging targets for metabolic and inflammatory disorders. The melanocortin system is highly conserved and includes five receptors (MC1R–MC5R) with distinct tissue distributions and functions. MC3R is predominantly expressed in the central nervous system, particularly in the hypothalamus, where it modulates food intake and energy expenditure. Recent studies have identified accessory proteins, such as MRAP2, that directly interact with MC3R to enhance its signaling, adding a layer of complexity to the binding and activation process. Moreover, mutations in GNAS, which encodes the Gs alpha subunit downstream of melanocortin receptors, are associated with obesity, underscoring the clinical importance of this pathway. Thus, GO:0031781 represents a focal point for researchers investigating the molecular basis of metabolic regulation and inflammation.
type 3 melanocortin receptor binding At A Glance
| GO ID | GO:0031781 |
|---|---|
| GO term | type 3 melanocortin receptor binding |
| Ontology | molecular_function |
| Synonym | type 3 melanocortin receptor ligand |
| Major function | Binding to the type 3 melanocortin receptor (MC3R), initiating receptor-mediated signaling |
| Related receptor | MC3R (melanocortin 3 receptor), a class A GPCR |
| Key accessory protein | MRAP2, which enhances MC3R signaling |
| Associated diseases | Obesity, metabolic syndrome, inflammation |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, pharmacological characterization |
What Is GO:0031781?
According to the Gene Ontology, GO:0031781 (type 3 melanocortin receptor binding) is defined as the binding to a type 3 melanocortin receptor. In other words, it is the molecular function of a ligand (such as a melanocortin peptide or a synthetic agonist) physically interacting with MC3R. This term is used to annotate gene products that exhibit selective binding to MC3R, distinguishing them from binders of other melanocortin receptor subtypes.
Why Is type 3 melanocortin receptor binding Important in Cell Biology?
GO:0031781 is important because MC3R binding is a critical control point in the melanocortin pathway, which regulates energy homeostasis, inflammation, and neuroendocrine functions. Dysregulation of this binding can lead to metabolic disorders such as obesity and may contribute to inflammatory diseases. Understanding the molecular details of MC3R binding can inform the development of targeted therapeutics, including small-molecule agonists or antagonists. Furthermore, the interaction of MC3R with accessory proteins like MRAP2 modulates binding affinity and signaling efficacy, offering additional targets for intervention.
• MC3R binding is a key step in the regulation of food intake and energy expenditure.
• Genetic variants in melanocortin receptors, including MC4R, are linked to obesity protection, highlighting the therapeutic potential of modulating receptor binding.
• MC3R has been proposed as a target for anti-inflammatory therapy, linking receptor binding to immune regulation.
• Accessory proteins such as MRAP2 directly interact with MC3R to enhance signaling, revealing a regulatory mechanism for binding.
• Obesity-associated GNAS mutations affect the melanocortin pathway downstream of receptor binding, underscoring clinical relevance.
• Pharmacological characterization of MC3R mutants helps elucidate structure-function relationships of binding.
• CRISPR-based models enable precise dissection of MC3R binding in vivo.
• The melanocortin system is conserved across species, allowing translational research from animal models to humans.
• Dysregulated MC3R binding may contribute to metabolic dysregulation in hepatocellular carcinoma and other cancers.
• Understanding MC3R binding can guide the design of biased ligands for selective therapeutic effects.
Molecular Mechanism of type 3 melanocortin receptor binding
Ligand Recognition and Binding to MC3R
In simple terms: A ligand molecule docks onto the MC3R receptor like a key in a lock.
The binding of a ligand to MC3R involves specific interactions between the ligand and the receptor's extracellular loops and transmembrane domains. Melanocortin peptides, such as alpha-MSH, bind to MC3R with high affinity, triggering conformational changes in the receptor. This binding is the first step in receptor activation and is subject to modulation by accessory proteins.
Role of MRAP2 in Enhancing MC3R Binding and Signaling
In simple terms: MRAP2 acts as a helper protein that makes the receptor more responsive to ligands.
MRAP2 directly interacts with MC3R to enhance its signaling. This interaction likely stabilizes the receptor in a conformation that favors ligand binding or promotes efficient G-protein coupling. The presence of MRAP2 can increase the potency and efficacy of MC3R agonists, thereby modulating the physiological response to melanocortin peptides.
G-Protein Coupling and Downstream Signaling
In simple terms: Once the ligand binds, the receptor activates a G-protein that relays the signal inside the cell.
MC3R is a Gs-coupled receptor; upon ligand binding, it activates the Gs protein, leading to increased intracellular cAMP levels. This signaling cascade ultimately affects neuronal activity and gene expression. Mutations in GNAS, which encodes the Gs alpha subunit, can disrupt this pathway and are associated with obesity.
Regulation by Accessory Proteins and Genetic Variants
In simple terms: Other proteins and genetic changes can tweak how well the receptor binds its ligand.
Beyond MRAP2, other MRAP family proteins may influence MC3R binding, although their roles are less defined. Naturally occurring mutations in MC3R can alter ligand binding affinity or signaling, as shown by pharmacological characterization of chicken MC3R mutants. These variants provide insights into structure-function relationships and may contribute to disease susceptibility.
Key Genes Involved in GO:0031781 type 3 melanocortin receptor binding
The following genes and proteins are directly involved in or regulate type 3 melanocortin receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MC3R | Encodes the type 3 melanocortin receptor, the primary binding target | Central to energy homeostasis and inflammation; target for anti-inflammatory therapy |
| POMC | Precursor of melanocortin peptides that bind MC3R | Provides endogenous ligands for MC3R; mutations cause obesity |
| MRAP2 | Accessory protein that enhances MC3R signaling | Directly interacts with MC3R to modulate binding and signaling |
| MRAP | Melanocortin receptor accessory protein | May influence MC3R trafficking and binding, though less characterized |
| GNAS | Encodes Gs alpha subunit downstream of MC3R | Mutations associated with obesity and metabolic disorders |
| MC4R | Another melanocortin receptor with overlapping functions | Gain-of-function variants protect against obesity; informs MC3R research |
| AGRP | Agouti-related peptide, antagonist of MC3R/MC4R | Modulates receptor binding and energy balance |
| ASIP | Agouti signaling protein, antagonist | Regulates melanocortin receptor binding in peripheral tissues |
| GPR45 | Orphan GPCR modulating Gαs at primary cilia | May interact with melanocortin pathway in hypothalamic neurons |
| ADCYAP1 | Pituitary adenylate cyclase-activating polypeptide | Potential modulator of melanocortin signaling |
| LEPR | Leptin receptor, upstream of melanocortin system | Regulates POMC and AGRP expression, affecting MC3R ligands |
| STAT3 | Transcription factor downstream of leptin signaling | Controls POMC expression, influencing MC3R ligand availability |
| PCSK1 | Prohormone convertase 1 | Processes POMC into active melanocortin peptides |
| PCSK2 | Prohormone convertase 2 | Processes POMC into active melanocortin peptides |
| CART | Cocaine- and amphetamine-regulated transcript | Anorexigenic peptide co-expressed with POMC, may modulate MC3R signaling |
| NPY | Neuropeptide Y | Orexigenic peptide that may influence melanocortin pathway |
| BDNF | Brain-derived neurotrophic factor | Downstream of melanocortin signaling in energy balance |
| SIM1 | Single-minded 1 transcription factor | Regulates hypothalamic development and melanocortin gene expression |
How Is type 3 melanocortin receptor binding Regulated?
The binding activity of MC3R is regulated at multiple levels. Accessory proteins such as MRAP2 directly interact with MC3R to enhance its signaling, likely by stabilizing the receptor in a ligand-binding-competent conformation. Other MRAP family members may also modulate receptor trafficking and function, although their specific roles in MC3R binding are less clear. Additionally, genetic variants in MC3R can alter ligand binding affinity and signaling efficacy, as demonstrated by pharmacological characterization of mutant receptors. Downstream, the Gs-cAMP pathway is subject to regulation by GNAS mutations, which can affect the cellular response to MC3R binding. Hormonal signals such as leptin regulate the expression of POMC and AGRP, thereby controlling the availability of endogenous ligands for MC3R.
type 3 melanocortin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MC3R | Obesity, inflammation | MC3R knockout mouse; CRISPR point mutation in MC3R |
| MRAP2 | Obesity, metabolic syndrome | MRAP2 knockout mouse; knock-in of human variants |
| GNAS | Obesity, metabolic disorders | Gs alpha knockout; point mutation knock-in |
| MC4R | Obesity protection | MC4R gain-of-function knock-in mouse |
| POMC | Obesity, adrenal insufficiency | POMC knockout; overexpression models |
Obesity and Metabolic Disorders
MC3R and its binding activity are critically involved in energy homeostasis. Genetic studies have shown that gain-of-function variants in MC4R, a related receptor, protect against obesity, highlighting the therapeutic potential of modulating melanocortin receptor binding. Mutations in GNAS, which encodes the Gs alpha subunit downstream of MC3R, are associated with obesity and metabolic syndrome. Furthermore, MC3R knockout mice exhibit increased adiposity, confirming its role in metabolic regulation.
Inflammation and Immune Regulation
MC3R has been proposed as a potential target for anti-inflammatory therapy. Activation of MC3R by melanocortin peptides can suppress inflammatory responses in various tissues, partly through modulation of immune cell activity. The binding of ligands to MC3R on immune cells may reduce cytokine production and mitigate inflammation, suggesting a therapeutic avenue for inflammatory diseases.
Cancer and Metabolic Dysregulation
Metabolic dysregulation is a hallmark of cancer, including hepatocellular carcinoma. The melanocortin system, through MC3R binding, may influence tumor metabolism and progression. Although direct evidence for MC3R in cancer is limited, the broader melanocortin pathway is implicated in metabolic reprogramming, and targeting receptor binding could offer novel therapeutic strategies.
From type 3 melanocortin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MC3R binding regulate food intake? | MC3R knockout mouse; conditional knockout in hypothalamus |
| How do point mutations in MC3R affect ligand binding? | CRISPR point mutation knock-in in cell lines; pharmacological characterization |
| Does MRAP2 enhance MC3R signaling in vivo? | MRAP2 knockout and knock-in mouse models |
| Can overexpression of MC3R rescue metabolic phenotypes? | Transgenic overexpression of MC3R in neurons |
| What is the role of GNAS mutations in melanocortin signaling? | GNAS point mutation knock-in mice |
| How does MC3R binding affect inflammation? | MC3R knockout in immune cells; adoptive transfer models |
How to Study the type 3 melanocortin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Ligand binding affinity (Kd) and receptor density (Bmax) | Characterization of MC3R mutants |
| cAMP accumulation assay | G-protein coupling and signaling efficacy | Functional assessment of MC3R variants |
| CRISPR knockout | Loss-of-function phenotypes | In vivo role of MC3R in energy balance |
| CRISPR point mutation | Effect of specific amino acid changes on binding | Structure-function studies of MC3R |
| Knock-in reporter | Receptor localization and expression | Mapping MC3R-expressing neurons |
| Overexpression | Gain-of-function effects | Rescue experiments in knockout backgrounds |
| RNA-seq | Transcriptional changes downstream of MC3R binding | Identification of target genes |
| Proteomics | Protein interaction networks | Discovery of MC3R binding partners |
Pharmacological Characterization of MC3R Binding
Radioligand binding assays and cAMP accumulation assays are used to measure ligand binding affinity and efficacy at MC3R. These methods can be applied to wild-type and mutant receptors to assess the impact of genetic variants.
CRISPR-Based Genetic Models
CRISPR/Cas9 technology enables the generation of knockout, point mutation, knock-in, and overexpression models to study MC3R binding in vivo. These models allow causal interrogation of specific residues or regulatory elements.
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics can identify downstream targets and signaling networks activated by MC3R binding. These approaches help elucidate the broader biological impact of receptor activation.
Imaging and Neuroanatomical Techniques
Fluorescent tagging of MC3R and its ligands allows visualization of binding events in live cells or tissues. This can reveal spatial and temporal dynamics of receptor-ligand interactions.
How CRISPR Can Be Used to Study GO:0031781 type 3 melanocortin receptor binding
Knockout
CRISPR knockout of MC3R or its accessory proteins (e.g., MRAP2) in cell lines and animal models enables the study of loss-of-function phenotypes related to receptor binding. For example, MC3R knockout mice exhibit increased adiposity, confirming the receptor's role in energy homeostasis.
Point Mutation
Introducing specific point mutations into MC3R via CRISPR allows researchers to dissect the contribution of individual amino acids to ligand binding and signaling. This approach has been used to characterize naturally occurring MC3R variants.
Knock-in
Knock-in of tagged or humanized MC3R alleles can facilitate imaging and translational studies. For instance, knocking in a fluorescent tag enables real-time visualization of receptor trafficking and binding in vivo.
Overexpression
CRISPR-mediated overexpression of MC3R or its ligands can be achieved by inserting strong promoters or using transcriptional activators. Overexpression models help identify gain-of-function effects and potential therapeutic benefits.
How EDITGENE Supports type 3 melanocortin receptor binding Research
Researchers studying type 3 melanocortin receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, metabolic regulation, or inflammation. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for type 3 melanocortin receptor binding research.
Frequently Asked Questions About type 3 melanocortin receptor binding
What is GO:0031781?
GO:0031781 is the Gene Ontology term for type 3 melanocortin receptor binding, a molecular function describing the binding of a ligand to the MC3R receptor.
What genes are involved in type 3 melanocortin receptor binding?
Key genes include MC3R (the receptor), POMC (ligand precursor), MRAP2 (accessory protein), and GNAS (downstream signaling).
What diseases are associated with MC3R binding?
MC3R binding is linked to obesity, metabolic disorders, and inflammation.
How is MC3R binding regulated?
It is regulated by accessory proteins like MRAP2, genetic variants, and hormonal signals such as leptin.
What research methods are used to study MC3R binding?
Common methods include radioligand binding assays, cAMP assays, CRISPR knockout/knock-in models, and transcriptomics.
Can CRISPR be used to study MC3R binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect MC3R binding in vitro and in vivo.
What is the role of MRAP2 in MC3R binding?
MRAP2 directly interacts with MC3R to enhance its signaling, likely by stabilizing the receptor in a ligand-binding-competent state.
Are there therapeutic implications of MC3R binding?
Yes, targeting MC3R binding could treat obesity and inflammatory diseases, as suggested by genetic and pharmacological studies.
How does MC3R binding affect energy balance?
MC3R binding in the hypothalamus modulates food intake and energy expenditure, influencing body weight.
What cell models are available for MC3R research?
EDITGENE offers custom CRISPR knockout, point mutation, knock-in, and overexpression cell models for MC3R and related genes.
Conclusion
GO:0031781 (type 3 melanocortin receptor binding) is a fundamental molecular function that governs MC3R-mediated signaling, with critical roles in energy homeostasis, inflammation, and metabolic disease. Understanding the precise mechanisms of ligand binding, the influence of accessory proteins like MRAP2, and the impact of genetic variants is essential for developing targeted therapies. CRISPR-based models and advanced pharmacological assays provide robust tools to dissect this binding event and its downstream consequences. As research continues to uncover the complexities of the melanocortin system, GO:0031781 will remain a focal point for therapeutic innovation in obesity and inflammatory disorders.
References
- 1. Du D et al.. 2022. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.. Acta Pharm Sin B 12(2):558-580 PMID: 35256934
- 2. Xun Y et al.. 2025. GPR45 modulates Gα(s) at primary cilia of the paraventricular hypothalamus to control food intake.. Science 388(6751):eadp3989 PMID: 40472089
- 3. Lotta LA et al.. 2019. Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect against Obesity.. Cell 177(3):597-607.e9 PMID: 31002796
- 4. Lam CW et al.. 2004. Melanocortin receptor type 3 as a potential target for anti-inflammatory therapy.. Curr Drug Targets Inflamm Allergy 3(3):311-5 PMID: 15379600
- 5. Clark AJ et al.. 2017. Promiscuity among the MRAPs.. J Mol Endocrinol 58(3):F1-F4 PMID: 28213370
- 6. Mendes de Oliveira E et al.. 2021. Obesity-Associated GNAS Mutations and the Melanocortin Pathway.. N Engl J Med 385(17):1581-1592 PMID: 34614324
- 7. Jamaluddin A et al.. 2025. The accessory protein MRAP2 directly interacts with melanocortin-3 receptor to enhance signaling.. Sci Signal 18(917):eadu4315 PMID: 41401256
- 8. Zhang HJ et al.. 2021. Pharmacological characterization of three chicken melanocortin-3 receptor mutants.. Domest Anim Endocrinol 74:106507 PMID: 32841887
